Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 16/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 14/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 14/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | CRHR1 | P34998 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6876424 | 0.82 | CYP3A4 (0.50) | ADORA2BADORA2AADORA1CYP3A4TDP1 | |
| SCHEMBL4128905 | 0.77 | ALDH1A1 (0.61) | CYP3A4TDP1ALDH1A1 | |
| SCHEMBL6874897 | 0.76 | CRHR1 (0.38) | ADORA2BADORA2AADORA1CYP3A4TDP1 | |
| SCHEMBL5713556 | 0.76 | ADORA2B (0.65) | ADORA2BADORA2AADORA1 | |
| SCHEMBL6867678 | 0.75 | ADORA2B (0.59) | ADORA2BADORA2AADORA1CYP3A4TDP1 | |
| SCHEMBL6876108 | 0.74 | ADORA2B (0.79) | ADORA2BADORA2AADORA1 | |
| SCHEMBL6876336 | 0.73 | CYP3A4 (0.43) | ADORA2BADORA2AADORA1CYP3A4TDP1 | |
| SCHEMBL6875429 | 0.73 | TDP1 (0.56) | CYP3A4TDP1ALDH1A1 | |
| SCHEMBL6872814 | 0.73 | ADORA2B (0.63) | ADORA2BADORA2AADORA1 | |
| SCHEMBL6878206 | 0.71 | ADORA2B (0.39) | ADORA2BADORA2AADORA1CRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1583752-B1 | CYCLIZATION PROCESS FOR SUBSTITUTED BENZOTHIAZOLE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2006-08-16 | — | — | EP | disclosed |
| US-7087761-B2 | Cyclization process for substituted benzothiazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-08-08 | — | — | US | disclosed |
| EP-1583752-A2 | CYCLIZATION PROCESS FOR SUBSTITUTED BENZOTHIAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-10-12 | — | — | EP | disclosed |
| EP-1456188-A1 | 7-AMINO-BENZOTHIAZOLE DERIVATIVES AS ADENOSINE RECEPTOR LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-09-15 | — | — | EP | disclosed |
| WO-2004060879-A2 | CYCLIZATION PROCESS FOR SUBSTITUTED BENZOTHIAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2004-07-22 | — | — | WO | disclosed |
| US-20040138465-A1 | Cyclization process for substituted benzothiazole derivatives | HOFFMANN-LA ROCHE INC. | 2004-07-15 | — | — | US | disclosed |
| US-6713499-B2 | ADENOSINE RECEPTOR AGONIST | HOFFMAN-LA ROCHE INC. | 2004-03-30 | — | — | US | disclosed |
| US-20030153566-A1 | 7-Amino-benzothiazole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2003-08-14 | — | — | US | disclosed |
| WO-2003053946-A1 | 7-AMINO-BENZOTHIAZOLE DERIVATIVES AS ADENOSINE RECEPTOR LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153566-A1 | 7-Amino-benzothiazole derivatives | ADORA1, ADORA2A, ADORA3 | ADORA2B 4/4885ADORA2A 2/4885ADORA1 1/4885 |
| US-20040138465-A1 | Cyclization process for substituted benzothiazole derivatives | CBR3, CBR1, OXTR | ADORA2B 3446/4885ADORA2A 4511/4885ADORA1 3630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.